{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(2)"],"submitter":["Watanabe J"],"funding":["Taiho Pharmaceutical Co Ltd"],"pubmed_abstract":["<h4>Background</h4>The ACTS-CC 02 trial demonstrated that S-1 plus oxaliplatin (SOX) was not superior to tegafur-uracil and leucovorin (UFT/LV) in terms of disease-free survival (DFS) as adjuvant chemotherapy for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries). We now report the final overall survival (OS) and subgroup analysis according to the pathological stage (TNM 7th edition) for treatment efficacy.<h4>Patients and methods</h4>Patients who underwent curative resection for pathologically confirmed high-risk stage III colon cancer were randomly assigned to receive either UFT/LV (300 mg/m<sup>2</sup> of UFT and 75 mg/day of LV on days 1-28, every 35 days, five cycles) or SOX (100 mg/m<sup>2</sup> of oxaliplatin on day 1 and 80 mg/"],"journal":["ESMO open"],"pagination":["100077"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7966838"],"repository":["biostudies-literature"],"pubmed_title":["S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial."],"pmcid":["PMC7966838"],"pubmed_authors":["Kusumoto T","Baba H","Tanaka C","Tomita N","Takenaka N","Yamauchi J","Sasaki S","Maeda A","Teshima J","Uetake H","Boku N","Morita S","Yoshida K","Sakamoto Y","Yokota M","Kotake K","Aiba K","Watanabe J","Sugihara K","Takahashi K","Itabashi M"],"additional_accession":[]},"is_claimable":false,"name":"S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial.","description":"<h4>Background</h4>The ACTS-CC 02 trial demonstrated that S-1 plus oxaliplatin (SOX) was not superior to tegafur-uracil and leucovorin (UFT/LV) in terms of disease-free survival (DFS) as adjuvant chemotherapy for high-risk stage III colon cancer (any T, N2, or positive nodes around the origin of the feeding arteries). We now report the final overall survival (OS) and subgroup analysis according to the pathological stage (TNM 7th edition) for treatment efficacy.<h4>Patients and methods</h4>Patients who underwent curative resection for pathologically confirmed high-risk stage III colon cancer were randomly assigned to receive either UFT/LV (300 mg/m<sup>2</sup> of UFT and 75 mg/day of LV on days 1-28, every 35 days, five cycles) or SOX (100 mg/m<sup>2</sup> of oxaliplatin on day 1 and 80 mg/","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-22T08:17:16.742Z","creation":"2025-04-05T22:29:08.813Z"},"accession":"S-EPMC7966838","cross_references":{"pubmed":["33714860"],"doi":["10.1016/j.esmoop.2021.100077"]}}